Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Antimicrobial Agents and Chemotherapy|February 5, 2014
Pharmacokinetics of isoniazid in low-birth-weight and premature infantsA Bekker, H S Schaaf, H I Seifart, et al.
Pediatric Neurosurgery|October 30, 1998
Massive posterior fossa tuberculous abscess developing in a young child treated for miliary tuberculosis. Possible role of very rapid acetylation of isoniazidJ F Schoeman, A Morkel, H I Seifart, et al.
South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde|June 4, 2013
The pharmacokinetics of enteral antituberculosis drugs in patients requiring intensive careC F N Koegelenberg, A Nortje, U Lalla, et al.
Archives of Disease in Childhood|May 24, 2005
Isoniazid pharmacokinetics in children treated for respiratory tuberculosisH S Schaaf, D P Parkin, H I Seifart, et al.
Expert Review of Anti-Infective Therapy|October 16, 2004
Early bactericidal activity of antituberculosis agentsP R Donald, F A Sirgel, A Venter, et al.
Antimicrobial Agents and Chemotherapy|October 5, 2011
Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendationsS Thee, J A Seddon, P R Donald, et al.
European Journal of Clinical Pharmacology|May 17, 2007
The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazidP R Donald, D P Parkin, H I Seifart, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 17, 2004
The influence of human N-acetyltransferase genotype on the early bactericidal activity of isoniazidP R Donald, F A Sirgel, A Venter, et al.
American Journal of Respiratory and Critical Care Medicine|October 6, 1997
The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosisP R Donald, F A Sirgel, F J Botha, et al.
American Journal of Respiratory and Critical Care Medicine|May 1, 1997
Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosisD P Parkin, S Vandenplas, F J Botha, et al.
Pageof 4